Determination of the Effect of Age and Gender on the Pharmacokinetics (PK) and Tolerability of a Single Dose of Finafloxacin HCl (FIN) in Healthy Volunteers

L. Mooney¹, M. Murphy², M. Kabbaj³, A. Vente⁴, H. Labischinski¹, and D. Swearingen⁴

¹Merlion Pharmaceuticals GmbH, Berlin, Germany, ²Celerion, Belfast, United Kingdom, ³Celerion, Zurich, Switzerland, ⁴Celerion, Tempe, AZ.

Abstract

Introduction: FIN is a novel fluoroquinolone that exhibits antibacterial and pharmacokinetic properties under acidic conditions which offer a number of desirable characteristics.

Methods: The study was conducted under approval of the Celerion IRB, the FDA IND # 105937, and in accordance with GCP. This was a single-center, open-label study in 40 healthy subjects (10 young adult males, 10 young adult females, 10 elderly adult males, and 10 elderly adult females). All subjects received a single oral dose of 400 mg FIN (2 x 200 mg tablets).

Results: Following a single dose of 400 mg, the mean peak exposure (Cmax) of FIN was similar in elderly (85.5 ± 28.5) and young (84.3 ± 22.2) subjects. The average exposure (AUC0-24) was approximately 10% greater in elderly (22.46 ± 3.50) versus young (20.69 ± 3.85) subjects (not statistically significant). Mean exposure was similar in males and females (Cmax; 2-fold difference) and Creas was consistently higher in females (85.8 - 46.7) than males (46.7 - 46.7). The mean T½ of FIN was comparable in both genders within each age group. Renal clearance was reduced in the elderly group. In total 23 AEs (21 mild and 2 moderate) and no serious AEs were observed. There were no significant findings in clinical laboratory values, vital signs, ECGs, and physical examinations.

Conclusions: There were no statistically significant age or gender effects on FIN PK except on urinary excretion (age) and peak exposure (gender). The administration of a single oral dose of 400 mg FIN was safe and well tolerated in the young and elderly male and female subjects in this study.

Background

• Finafloxacin is a novel pH activated, broad spectrum fluoroquinolone in development for infection indications in the hospital and critical care setting [1, 2]
• Finafloxacin exhibits enhanced activity at low pH and under other environmental conditions associated with infection [1, 2]
• Finafloxacin exhibits bactericidal activity against forms of quiescent growth, thought to be relevant in vivo e.g. non-growing cells, biofilms and persisters [3]
• Other fluoroquinolones lose activity under such conditions. Consequently, finafloxacin exhibited superior activity in a series of in vitro studies.
• The activity of finafloxacin under infection relevant conditions and against infection relevant growth forms in combination with the high dosing potential predicted from its safety profile [6, 7], suggest finafloxacin will offer improved properties over currently marketed fluoroquinolones.

Previous clinical studies have indicated that finafloxacin is well tolerated with few treatment-related AEs. As a part of the clinical development of finafloxacin, other PK studies are required to determine the effect of other variables on the PK profile of finafloxacin.

The primary objective of the study was as follows:
• To assess the PK profile of finafloxacin in healthy young and elderly volunteers.

The secondary objective of the study was as follows:
• To determine the safety and tolerability of finafloxacin in healthy young and elderly volunteers.

Methods

• All pertinent study documents were reviewed by the independently functioning Celerion Institutional Review Board (IRB) prior to study initiation. The IRB operates in accordance with the U.S. Code of Federal Regulations (21 CFR Part 56) and International Conference on Harmonization (ICH) guidelines. This study was conducted under the FDA investigational new drug number IND 106,076.
• This was a single-center, open-label, single-dose study in 40 healthy subjects. The subjects were assigned to 1 of 4 groups comprised of the following: young healthy adult males, young healthy adult females, elderly healthy adult males, and elderly healthy adult females.
• The subjects fasted for 10 hours and were administered 400 mg finafloxacin (as 2 x 200 mg tablets) administered with 240 mL of water.
• Blood samples were withdrawn at the following times, predose and at 30 minutes, 45 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours post dose.
• Urine samples were collected from subjects over a 24-hour postdose period at the following intervals: baseline (predose), 6–8 hours, 8–10 hours, 12–14 hours, and 24–48 hours.
• Finafloxacin PK parameters were summarized using descriptive statistics. The comparisons between the four age–gender groups administered 400 mg finafloxacin were assessed using an analysis of variance (ANOVA).
• The safety assessments included laboratory evaluations, physical examinations, AEs, standard 10 lead ECG parameters, and vital sign assessments.

Results

See tables and figures for detailed data. Summary of the Mean Pharmacokinetic Parameters for Plasma Finafloxacin in all Treatment Groups

Conclusions

• The average systemic availability (AUC0-24) of finafloxacin was approximately 10% greater in elderly versus young subjects (not statistically significant). Mean systemic exposure was similar in males and females (16% difference).
• The mean peak exposure (Cmax) of FIN was similar in elderly (85.5 ± 28.5) and young (84.3 ± 22.2) subjects, but slightly higher in females versus males.
• Urinary excretion of finafloxacin (based on CumAe0-24 and Rmax) was significantly lower (by 42% – 56%) in elderly compared to young subjects and was similar between genders.
• There were no statistically significant age or gender effects on FIN PK except on urinary excretion (age) and peak exposure (gender).
• Overall, there were no major safety concerns found in the vital signs, safety laboratory, ECG, AE, or physical examination assessments associated with the administration of finafloxacin in young and elderly healthy male and female subjects.
• The administration of a single oral dose of 400-mg finafloxacin was safe and well tolerated in the young and elderly male and female subjects in this study.

References